New pill shows promise against tough lung cancer
Disease control
Recruiting now
This study tests a new daily pill called TRI-611 for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in differen…
Phase: PHASE1, PHASE2 • Sponsor: TRIANA Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC